Metabolic liver health: how to assess risk, catch dysfunction early, and more (AMA 88 sneak peek)
In a Nutshell
The liver is a central metabolic organ where dysfunction manifests early as metabolic stress and fat accumulation (MASLD/MASH), progressing to inflammation and fibrosis—the stage that drives cardiovascular disease, cancer, and liver-specific mortality. Key risk drivers include chronic caloric surplus, visceral fat, low muscle mass, and alcohol (especially with metabolic dysfunction), while resistance training and avoiding sugar-sweetened beverages are the highest-yield interventions for prevention and reversal. Standard liver enzymes and BMI often miss early disease, making body composition, ancestry, and metabolic phenotype essential for accurate risk assessment.
These notes were generated by AI and may contain inaccuracies.
The liver sits at the center of systemic metabolism for every macronutrient including glucose, fat, protein, and cholesterol, as well as ethanol. The liver is one of the first places to both promote and respond to stress from anywhere in the system. If circulating triglycerides are high, the liver gets involved. If glucose regulation is deteriorating, the liver is involved. If APOB or LDL cholesterol is climbing, the liver made those particles. The liver functions as a two-way mirror between systemic metabolic health and what's happening in the liver. Dysfunction of the liver is more of a parallel expression of systemic metabolic dysfunction. The leading cause of death in people with liver disease isn't liver failure. It's cardiovascular disease because a liver under metabolic stress is overproducing apo containing particles and amplifying the insulin resistance that drives atherosclerosis throughout the body.
Fatty liver disease affects more than 38% of the world's adult population. This isn't something that happens to some unfortunate person that you'll never meet. It will happen to nearly anyone in the developed world who isn't paying some attention.
The liver has over 300 functions that fit into four main categories. The first is detoxification, where the liver breaks down alcohol just as it would break down virtually any toxin that reaches the blood from food, drink, pharmaceuticals, or inhalation. Second, the liver is an immune organ, as the first place blood from the gut goes is to the liver through the portal system, making it one of the first responders to ingested toxins or bacterial leakage from the gut. Third is protein processing and secretion, as the liver is the site of synthesis for many of the most common proteins in our blood including albumin and vital clotting and platelet stimulating factors, apo, and peptide hormones like IGF-1. The fourth category is energy metabolism, where the liver plays a central role in the uptake and synthesis of circulating fats and cholesterol and is one of the most important organs for maintaining blood sugar.
After a meal, glucose rises, the pancreas releases insulin, and insulin tells the liver to absorb glucose and store it as glycogen. When fasting and glucose dips, insulin falls and the liver breaks glycogen back down and releases glucose into the circulation. When glucose runs really low, the liver can manufacture glucose on its own, turning into a glucose making organ. If there's too much sugar to store as glycogen, the liver converts it into triglycerides, packages it into apo lipoproteins, and ships them out.
A fasting blood glucose of 90 milligrams per deciliter means the entire bloodstream contains only about 4 and a half grams of glucose, roughly a teaspoon. Yet a single meal may contain many times that, easily 90 grams of glucose. Despite this, a healthy person rarely moves more than a teaspoon above baseline blood glucose. Someone with type 2 diabetes would rarely go above a teaspoon and a half at fasting. This reserve capacity to titrate out glucose in such fine amounts is exactly why early dysfunction is very easy to miss.
Metabolic liver disease moves through four stages. In the first stage, the liver becomes metabolically stressed. In the second stage, the liver starts storing excess energy as fat, a condition known as steatosis. The third stage is steatohepatitis, where excess fat being stored in the liver tips the liver into inflammation and the liver begins to injure itself. The fourth stage is the response to that injury where the liver starts to lay down scar tissue called fibrosis. The first three stages are largely reversible, while fibrosis is biologically reversible to varying degrees especially if caught on the very early side of things. Once the scarring accumulates such that the liver's architecture is disrupted, that becomes irreversible. The presence of fibrosis is what predicts the outcomes that we typically care about, especially cardiovascular disease, cancer, and even liver specific mortality.
Chronic calorie surplus is a primary driver of metabolic dysfunction. If you consume more calories than you expend consistently, the liver converts much of that excess energy into triglycerides through a process of de novo lipogenesis. The liver packages them into apo containing particles, namely VLDLs and LDLs, and ships them to adipose tissue for long-term storage. This is a normal healthy physiologic response that allows us to store energy when energy is abundant and draw from that when energy is scarce.
A fat cell functions as a warehouse. For a while, they will accept every shipment. But as they become progressively overfilled, they stop responding normally to insulin. One of the molecular hallmarks of that process is the accumulation of a lipid intermediate called diacylglycerol or DAG which interrupts insulin signaling. Once that happens, the warehouse starts malfunctioning and instead of simply storing fat, those adipocytes begin releasing fatty acids back into the bloodstream exactly what you don't want unless you're about to use them immediately.
The liver picks up those fatty acids as well as the fats from our diet because that's one of the primary jobs of energy balance. Eventually the same process develops here. Lipid intermediates begin to accumulate, insulin signaling becomes impaired, and the liver becomes insulin resistant.
Insulin normally tells the liver to do two things: stop releasing glucose into the bloodstream and stop making new fat. Because if insulin is high, you've just been fed, and if you're fed, you don't need to be putting glucose into the bloodstream or making new fat. As insulin resistance develops, the first signal fails before the second. So the liver continues releasing glucose even when blood sugar is already high while the pancreas responds by making more insulin which still drives fat production. This is called selective hepatic insulin resistance and it's one of the defining features of metabolic disease.
At first the liver exports those triglycerides in these apo containing particles which is why dyslipidemia always accompanies this. Eventually production outpaces export, so fat accumulates inside the liver and now we've reached stage two of the linear progression, which is steatosis.
The name of the disease changed recently to reference the cause of the disease and move away from the fat in the name, because fat is basically the end result of caloric excess but that excess isn't usually fat itself. Excess calories are often in the form of carbohydrates, glucose, or fructose. Previously this disease was called NAFLD for non-alcoholic fatty liver disease, and if it progressed to the inflammation damage stage it was NASH for non-alcoholic steatohepatitis. The NA in both of those stands for non-alcoholic, to differentiate that this was driven through excess energy but not through the damage specifically of alcohol. Now these things are called MASLD and MASH, which stand for metabolic dysfunction associated steatotic liver disease and steatohepatitis.
Steatosis is a giant warning sign but not liver damage yet. The liver is stuffing excess energy inventory into the manager's office because the shelves are full. Something is clearly wrong, but at the packaging facility, nothing is breaking yet. MASLD is diagnosed when that steatosis is accompanied by another cardiometabolic risk factor such as hypertension, pre-diabetes defined by hemoglobin A1C, type 2 diabetes, dyslipidemia, elevated BMI, or obesity. Liver fat accompanied by some other metabolic dysfunction is what we're looking for, and that's our second stage of both metabolic stress as well as fat in the liver.
The real damage begins when that fat burden triggers inflammation. Hepatocytes loaded past their limit actually start to die. Hepatocytes are the cells that make up the liver. Their death recruits immune cells which release inflammatory signals that spread to neighboring cells. That inflammation starts to disable insulin signaling through a second separate pathway, so the resistance is now coming from two directions at once. With even more insulin resistance, the neighboring cells now accumulate more fat and die too, creating a spreading wave where each cell death drives the next. This becomes a feed forward amplified loop.
That transition from fat accumulating to active inflammation is the move from stage two to stage three, which is called MASH. The liver responds to dying cells by laying down scar tissue, which is called fibrosis. As fibrosis accumulates, the liver moves towards cirrhosis, the end stage scarring where so much functioning tissue has been replaced that the liver can't even do its job anymore. This is also where cancer risk starts to climb dramatically. Fibrosis is where the really durable clinical risk lives.
Visceral fat is one of the most significant modifiers of liver risk. Not all fat is metabolically equal. Fat stored around your organs is actually more prone to releasing fatty acids even at baseline. The bigger factor is location. Visceral fat around the abdominal organs drains directly into the portal vein which is one of the two blood supplies that goes to the liver. Subcutaneous fat releases fatty acids that diffuse through the entire circulation first, so it's just far less concentrated in terms of a shot directly into the liver. Visceral fat bypasses all of that, making it the difference between someone yelling at you from across the house versus shouting directly into your ear.
In one cohort, visceral fat area which could be estimated by CT scans predicted steatosis independent of BMI and liver enzymes. Patients with greater than 200 cm squared of visceral fat had a 7 and a half fold greater increase of liver steatosis when compared to people below 100 cm squared. Among people with diagnosed MASLD in the NHANES database, the all-cause mortality ratio in the top quartile of visceral adiposity was nearly three and a half times that in the lowest quartile. So visceral fat predicts liver pathology and in the people who already have liver disease, visceral fat predicts a dramatically higher risk of death.
Skeletal muscle is a major glucose sink in the body and is hands down the largest sink of glucose in the body. It pulls blood sugar out of circulation and stores it as glycogen. Roughly speaking, about three quarters of your total capacity to store glucose is in your muscle and about a quarter of it's in your liver. Less muscle means less capacity to buffer glucose, so more of that burden lands on your liver. This is why you see metabolic liver disease in people that actually have normal BMI but are very low in muscle mass, which is called sarcopenic obesity or skinny fat.
Multiple longitudinal cohorts point out that more muscle predicts both fewer new cases of MASLD and higher rates of resolution. The single most striking figure comes from a large 7-year Korean cohort where people who gained the most muscle over the study resolved their MASLD at more than four times the rate of those who gained the least muscle. Whether it's prevention or reversal, resistance training is a non-negotiable if you're trying to address metabolic dysfunction.
In a randomized trial in 94 healthy men who drank moderate amounts of fructose, sucrose which is the 50/50 mix of fructose and glucose, or glucose sweetened beverages for seven weeks at weight stability, fructose and sucrose roughly doubled the liver's baseline fat-making machinery through the de novo lipogenesis pathway, while glucose did not. So at least in this study, fructose can behave differently from glucose in the human liver, and that shows up most cleanly in measurements of de novo lipogenesis.
On the harder outcome of actual steatosis, controlled feeding studies show the dominant driver is excess calories and not fructose itself. If you swap fructose isocalorically for other carbohydrates, liver fat barely moves. So calorie for calorie, the honest fructose specific signal is on lipogenesis which is an intermediate measure but not the final outcome. Where fructose earns its reputation is in the form that it arrives in, such as liquid sugar in soda or high fructose corn syrup laden beverages which are very calorie dense, don't make you feel full, and are trivially easy to consume. The cohort data do link sugar sweetened beverages to higher MASLD risk.
The practical advice is that cutting sugar sweetened beverages is absolutely one of the higher yield dietary moves for someone with insulin resistance or liver disease. The chief reason for that is the downstream effect on less calorie reduction. One of the things to counsel somebody on who has fatty liver disease is don't drink calories at all and especially don't drink carbohydrate calories and especially don't drink fructose containing calories.
Alcohol associated liver disease is more common than we give it credit for. Looking at people requiring liver transplants, more of those came from alcohol consumption than non-alcoholic consumption. Alcohol works through a different mechanism than caloric excess, but the outcome is almost the same, passing through steatosis, insulin resistance, fibrosis, and ultimately cirrhosis. Alcohol is very harmful if you combine it with metabolic dysfunction as is often the case, creating a two-pronged synergistic attack when calorie excess and alcohol co-occur.
The combination of metabolic dysfunction and alcohol consumption recently earned its own designation called metabolic and alcohol associated liver disease or MetALD. In a cohort study from the NHANES database in patients with existing cardiometabolic risk factors, steatosis alone wasn't associated with increased all-cause mortality if you already had a risk factor. But steatosis plus what they described as moderate and moderate plus alcohol consumption produced hazard ratios of 1.4 for all cause mortality, 2.35 for cancer mortality, and 15X for liver specific mortality versus people with no steatotic liver disease. That translates to a cause of death from anything is up 40%, death from cancer is up 135%, and from liver specific disease, death is up 1,400%.
Acetaldehyde is the primary driver of alcohol's harm on the liver and it accumulates faster the more you exceed about one drink per hour.
Binge drinking patterns may be more harmful than daily moderate consumption. Seven drinks in one evening is likely worse than one drink per night across seven consecutive nights, based on mechanistic understanding of alcohol's effects on the liver, though direct human data comparing binge versus daily drinking patterns for metabolic disease outcomes do not exist and are unlikely to be studied in randomized controlled trials.
The NHANES study relied on self-reported alcohol consumption data, which may represent either accurate reporting or slight underestimates. Men in the study reported consuming approximately 40 to 60 grams of alcohol per day, while women consumed slightly less. This translates to self-reported consumption of at least three drinks daily, potentially up to four drinks per day. The 60 grams of ethanol measurement corresponds to normal-sized drinks or potentially less when individuals pour their own drinks.
Many people can consume this amount of alcohol while remaining completely functional without obvious side effects. The findings are not limited to individuals with severe alcohol use disorders.
Baseline risk factors for liver disease fall into two categories: inherited genetic variants and hormonal influences that can change over time.
The most significant single gene variant is PNPLA3, where individuals carrying two copies of a particular variant have approximately 2x increased risk of liver fat accumulation. This elevated risk extends to inflammation and fibrosis development, even after accounting for standard metabolic risk factors.
A protective variant exists in the gene HSD17B13, representing a loss of function variant associated with lower liver enzymes and reduced fibrosis risk. This protective variant may partially offset the risk associated with PNPLA3 variants.
Additional genetic variants exist beyond these two primary ones.
The PNPLA3 risk variant occurs more frequently in individuals with Hispanic ancestry, contributing to increased population-level susceptibility to MASLD and MASH. Conversely, individuals of African ancestry show lower frequency of this risk variant, contributing to reduced clinical risk at the population level.
These genetic predispositions represent risk modifiers rather than deterministic outcomes. Two individuals with identical behaviors can have completely different liver health outcomes, demonstrating that genetic factors influence but do not determine metabolic liver disease development.
Standard BMI measurements can miss important body composition differences. Individuals of Asian ancestry often develop metabolic risk at lower and normal BMIs, partly because visceral adiposity can be higher at any given body weight in populations that genetically accumulate less subcutaneous fat.
Body weight and BMI serve as useful population-level tools but provide limited individual-level information. More nuanced measurements including total body fat and visceral fat provide clinically relevant data.
Premenopausal women have relative protection from liver fat accumulation due to estrogen's effects on restraining visceral and hepatic fat deposition. This protective effect diminishes after menopause, sometimes quite rapidly, leading to increased fatty liver prevalence and potentially more aggressive disease progression.
Risk assessment should incorporate ancestry, family history, genotype, and menopause status alongside metabolic phenotype evaluation. However, none of these factors replaces the fundamental assessment of an individual's actual metabolic phenotype.
Normal liver enzymes from annual blood work do not necessarily indicate healthy liver function. Most people assume normal liver enzymes confirm liver health, but this assumption may not hold true.
Keep Peter Attia MD in your library
Save the videos and channels worth coming back to, and find them again in one place.
